Musso G, et al. - In this meta-analysis of randomized, controlled trials, researchers tested the safety and effectiveness of dual sodium glucose cotransporter (SGLT) 1/2 inhibitor sotagliflozin in type 1 diabetes mellitus. Six randomized, placebo-controlled trials (n=3,238; duration 4-52 weeks) were included. Investigators found that sotagliflozin improved glycemic and non-glycemic outcomes (including markers of diabetic nephropathy) and decreased hypoglycemia rate and severe hypoglycemia in type 1 diabetes. According to findings, appropriate patient selection and down-titration of basal insulin dose could minimize the risk of diabetic ketoacidosis.